Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 0.74 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.74 |
| ▸ | BUB1 | O43683 | 1/20 | 0.74 |
| ▸ | STK10 | O94804 | 1/20 | 0.74 |
| ▸ | CARS1 | P49589 | 1/20 | 0.74 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.74 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.74 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.74 |
| ▸ | ABL1 | P00519 | 4/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.68 |
| ▸ | SRC | P12931 | 4/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.68 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31004062 | 1.00 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL20865234 | 0.88 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 | |
| Icotinib SCHEMBL29544144 | 0.85 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 | |
| Icotinib SCHEMBL5843603 | 0.85 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 | |
| Icotinib SCHEMBL29355667 | 0.85 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 | |
| Icotinib SCHEMBL31236202 | 0.84 | EGFR (0.98) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL15339251 | 0.84 | EGFR (0.79) | EGFRGAKRIPK2BUB1STK10 | |
| Icotinib SCHEMBL29376848 | 0.84 | EGFR (0.98) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL6797080 | 0.82 | EGFR (0.81) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL24329477 | 0.82 | EGFR (1.00) | EGFRABL1FGFR1SRCPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145634-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-08 | — | — | US | disclosed |
| WO-2024081447-A1 | EGFR INHIBITORS FOR TREATING LUNG CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20240043390-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-08 | — | — | US | disclosed |
| US-20230115366-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-13 | — | — | US | disclosed |
| US-11377451-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-05 | — | — | US | disclosed |
| US-11377451-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| US-20200290978-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200290978-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2019067543-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145634-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | EGFR 3/4885GAK 694/4885RIPK2 3236/4885 |
| US-11377451-B2 | Compositions and methods for treating cancer | TP53, EGFR, SLC2A1 | EGFR 2/4885GAK 387/4885RIPK2 2989/4885 |
| US-20230115366-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | EGFR 3/4885GAK 694/4885RIPK2 3236/4885 |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | EGFR 3/4885GAK 694/4885RIPK2 3236/4885 |
| US-20200290978-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | EGFR 2/4885GAK 672/4885RIPK2 3222/4885 |
| US-20240043390-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | EGFR 2/4885GAK 672/4885RIPK2 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.